SCHEMBL7607104

SCHEMBL7607104

CCOC(=O)c1cnc2c(c1)/C(=C/Nc1ccnn1CC)C(=O)N2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
PABPC1 P11940 1/20 0.35
APOBEC3A P31941 1/20 0.35
EIF4H Q15056 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
P2RY12 Q9H244 8/20 0.35
JMJD6 Q6NYC1 3/20 0.34
MDM2 Q00987 1/20 0.34
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
S1PR4 O95977 1/20 0.33
MAPT P10636 1/20 0.33
S1PR1 P21453 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
PAX8 Q06710 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7607108 1.00 ALDH1A1 (0.38) ALDH1A1PABPC1APOBEC3AEIF4HAPOBEC3G
SCHEMBL7614042 0.82 NTRK1 (0.41)
SCHEMBL7614047 0.82 NTRK1 (0.41)
SCHEMBL7606157 0.80 JAK3 (0.41) ALDH1A1MEN1MAPTKMT2A
SCHEMBL5873743 0.80 ALDH1A1 (0.46) ALDH1A1MEN1NPC1MAPTRAB9A
SCHEMBL7606158 0.80 JAK3 (0.41) ALDH1A1MEN1MAPTKMT2A
SCHEMBL5873740 0.80 ALDH1A1 (0.46) ALDH1A1MEN1NPC1MAPTRAB9A
SCHEMBL7613347 0.80 SMN1; SMN2 (0.40) ALDH1A1JMJD6MDM2MEN1NPC1
SCHEMBL7613340 0.80 SMN1; SMN2 (0.40) ALDH1A1JMJD6MDM2MEN1NPC1
SCHEMBL5873824 0.78 ALDH1A1 (0.37) ALDH1A1PABPC1APOBEC3AEIF4HAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX ALDH1A1 4171/4885PABPC1 2822/4885APOBEC3A 4549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.